Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Collaborative artificial intelligence and clinical evaluation of interstitial lung diseases : a call for interdisciplinary partnershipsIn: Science Bulletin , Jg. 70 2025, Nr. 4, S. 437 – 440DOI (Open Access)
-
Recurrent pulmonary alveolar proteinosis after lung transplantation : A case seriesIn: Respiratory Medicine , Jg. 244 2025, 108167DOI (Open Access)
-
‘Diagnosis and Treatment of Hypersensitivity Pneumonitis’ S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical ImmunologyIn: Respiration: International Journal of Thoracic Medicine 2025 , in pressDOI (Open Access)
-
Diagnostik und Therapie der exogen-allergischen Alveolitis : S2k-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. und der Deutschen Gesellschaft für Allergologie und klinische Immunologie e. V.In: Pneumologie , Jg. 78 2024, Nr. 12, S. 963 – 1002
-
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (Update) and Progressive Pulmonary Fibroses : S2k Guideline of the German Respiratory SocietyIn: Respiration: International Journal of Thoracic Medicine , Jg. 103 2024, Nr. 12, S. 782 – 810DOI (Open Access)
-
Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis : A German and Japanese cohort studyIn: Respiratory Research , Jg. 25 2024, Nr. 1, 405DOI (Open Access)
-
COVID-19 in patients with pulmonary alveolar proteinosis : A European multicentre studyIn: ERJ Open Research , Jg. 9 2023, Nr. 1, 00199-2022DOI (Open Access)
-
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis : Post-Hoc Analysis of Six Clinical StudiesIn: Advances in Therapy , Jg. 40 2023, Nr. 9, S. 3937 – 3955DOI (Open Access)
-
Erratum : Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler FibrosenIn: Pneumologie , Jg. 77 2023, Nr. 2, S. e1
-
GLPG1205 for idiopathic pulmonary fibrosis : A phase 2 randomised placebo-controlled trialIn: European Respiratory Journal (ERJ) , Jg. 61 2023, Nr. 3, 2201794DOI (Open Access)
-
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare VariantsIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 207 2023, Nr. 9, S. 1194 – 1202DOI (Open Access)
-
Imbalanced distribution of regulatory T cells and Th17.1 cells in the peripheral blood and BALF of sarcoidosis patients : Relationship to disease activity and the fibrotic radiographic phenotypeIn: Frontiers in Immunology , Jg. 14 2023, 1185443DOI (Open Access)
-
Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen : S2k-Leitline der Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e. V.In: Pneumologie , Jg. 77 2023, Nr. 2, S. 94 – 119
-
S1-Leitlinie Interdisziplinäre Diagnostik interstitieller Lungenerkrankungen im ErwachsenenalterIn: Pneumologie , Jg. 77 2023, Nr. 5, S. 269 – 302DOI (Open Access)
-
Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung DiseaseIn: Journal of Clinical Medicine (JCM) , Jg. 12 2023, Nr. 3, 1173DOI (Open Access)
-
Thoracic pain in patients with chronic interstitial lung disease : an underestimated symptomIn: Frontiers in Medicine , Jg. 10 2023, 1147555DOI, Online Volltext (Open Access)
-
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical TrialsIn: JAMA: Journal of the American Medical Association , Jg. 329 2023, Nr. 18, S. 1567 – 1578DOI (Open Access)
-
A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial PneumoniaIn: Pneumologie , Jg. 76 2022, Nr. 01, S. 25 – 34DOI (Open Access)
-
A transcriptomics-based meta-analysis identifies a cross-tissue signature for sarcoidosisIn: Frontiers in Medicine , Jg. 9 2022, 960266DOI (Open Access)
-
Comparison of a 22G Crown-Cut Needle with a Conventional 22G Needle with EBUS Guidance in Diagnosis of SarcoidosisIn: Lung , Jg. 200 2022, Nr. 5, S. 633 – 641DOI (Open Access)
-
Double Lung Transplantation for Idiopathic Pulmonary Fibrosis in a Patient with a History of Liver Transplantation and Prolonged Journey for Disease-Specific Antifibrotic TherapyIn: Case Reports in Pulmonology , Jg. 2022 2022, 4054339DOI (Open Access)
-
IL-9 and IL-9 receptor expression in lymphocytes from bronchoalveolar lavage fluid of patients with interstitial lung diseaseIn: Immunobiology , Jg. 227 2022, Nr. 5, 152258
-
Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemicIn: Exploration , Jg. 2 2022, Nr. 5, 20210082DOI (Open Access)
-
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases : Data from the randomized controlled INBUILD trialIn: Respiratory Research , Jg. 23 2022, Nr. 1, 85DOI (Open Access)
-
Transbronchial cryobiopsy : the right procedure for the right patient in the right place at the right timeIn: European Respiratory Journal (ERJ) , Jg. 60 2022, Nr. 5, 2201648
-
Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?In: Therapeutic Advances in Musculoskeletal Disease , Jg. 13 2021, S. 1 – 21DOI (Open Access)
-
Bronchoscopic performance of bronchoalveolar lavage in Germany - A call for standardizationIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 38 2021, Nr. 1
-
Immunohistochemical Detection of Potential Microbial Antigens in Granulomas in the Diagnosis of SarcoidosisIn: Journal of Clinical Medicine (JCM) , Jg. 10 2021, Nr. 5, 983DOI (Open Access)
-
Misconceptions regarding symptoms of sarcoidosisIn: The Lancet Respiratory Medicine , Jg. 9 2021, Nr. 8, S. 816 – 818
-
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosisIn: European Respiratory Journal (ERJ) , Jg. 57 2021, Nr. 2, S. 1902442DOI (Open Access)
-
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF) : A double-blind, randomised, placebo-controlled, phase 2b trialIn: The Lancet Respiratory Medicine , Jg. 9 2021, Nr. 5, S. 476 – 486DOI (Open Access)
-
Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPFIn: Orphanet Journal of Rare Diseases , Jg. 16 2021, Nr. 1, 111DOI, Online Volltext (Open Access)
-
S2K Guideline for Diagnosis of Idiopathic Pulmonary FibrosisIn: Respiration: International Journal of Thoracic Medicine , Jg. 100 2021, Nr. 3, S. 238 – 271DOI (Open Access)
-
Sprachliche Validierung des Fibrose-Fragebogens zur Erfassung der Lebensqualität bei Patienten mit idiopathischer Lungenfibrose und idiopathischer nichtspezifischer interstitieller PneumonieIn: Pneumologie , Jg. 75 2021, Nr. 10, S. 753 – 760
-
Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis : results of a Delphi surveyIn: European Respiratory Journal (ERJ) , Jg. 57 2021, Nr. 4, S. 2004219DOI (Open Access)
-
The Role of Diverse Immune Cells in SarcoidosisIn: Frontiers in Immunology , Jg. 12 2021, 788502DOI (Open Access)
-
The diagnosis and treatment of pulmonary fibrosisIn: Deutsches Ärzteblatt international , Jg. 118 2021, Nr. 9, S. 152 – 162DOI (Open Access)
-
A Comparison of Existing Questionnaires for Identifying the Causes of Interstitial and Rare Lung DiseasesIn: Respiration: International Journal of Thoracic Medicine , Jg. 99 2020, Nr. 2, S. 119 – 124
-
Azathioprine for Connective Tissue Disease-Associated Interstitial Lung DiseaseIn: Respiration: International Journal of Thoracic Medicine , Jg. 99 2020, Nr. 8, S. 628 – 636
-
Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosisIn: European Respiratory Review (ERR) , Jg. 29 2020, Nr. 155, 190146DOI (Open Access)
-
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE) : A phase 2, randomised, double-blind, placebo-controlled trialIn: The Lancet Respiratory Medicine , Jg. 8 2020, Nr. 1, S. 25 – 33
-
Progressive fibrosing interstitial lung disease : clinical uncertainties, consensus recommendations, and research prioritiesIn: The Lancet Respiratory Medicine , Jg. 8 2020, Nr. 9, S. 925 – 934DOI (Open Access)
-
S2K-Leitlinie zur Diagnostik der idiopathischen LungenfibroseIn: Pneumologie , Jg. 74 2020, Nr. 5, S. 263 – 293
-
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease : Data from the SENSCIS trialIn: Annals of the Rheumatic Diseases (ARD) , Jg. 79 2020, Nr. 11, S. 1478 – 1484DOI (Open Access)
-
Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: A prospective multicentre trialIn: European Respiratory Journal (ERJ) , Jg. 56 2020, Nr. 6, S. 1901520DOI (Open Access)
-
Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis : German and Japanese Cohort StudyIn: Journal of Clinical Medicine (JCM) , Jg. 8 2019, Nr. 12, 2069DOI (Open Access)
-
Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipientsIn: Transplant Immunology , Jg. 52 2019, S. 40 – 44
-
Correction to: The burden of sarcoidosis symptoms from a patient perspectiveIn: Lung , Jg. 197 2019, Nr. 2, S. 163DOI (Open Access)
-
Diagnostic value of BAL lymphocytosis in patients with indeterminate for usual interstitial pneumonia imaging patternIn: European Respiratory Journal (ERJ) , Jg. 54 2019, Nr. 5 , Article-No: 1901144DOI (Open Access)
-
Die Rolle der Luftschadstoffe für die Gesundheit : Eine Replik auf die Expertise der Internationalen Gesellschaft für Umweltepidemiologie (ISEE) und der European Respiratory Society (ERS)In: Pneumologie , Jg. 73 2019, Nr. 5, S. 274 – 287
-
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosisIn: Respiratory Research , Jg. 20 2019, Nr. 1, S. 55DOI (Open Access)
-
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisIn: Chest , Jg. 155 2019, Nr. 4, S. 712 – 719DOI (Open Access)
-
Erratum zu: Differenzialdiagnose interstitieller Lungenerkrankungen – „Interstitial pneumonia with autoimmune features“ (IPAF)In: Der Pneumologe , Jg. 16 2019, Nr. 1, S. 39DOI (Open Access)
-
Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?In: European Respiratory Journal (ERJ) , Jg. 53 2019, Nr. 2, S. 1800994DOI (Open Access)
-
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis : results from the open-label extension study, INPULSIS-ONIn: The Lancet Respiratory Medicine , Jg. 7 2019, Nr. 1, S. 60 – 68
-
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairmentIn: Respiratory Medicine , Jg. 153 2019, S. 44 – 51DOI (Open Access)
-
Quantitative lipidomics in pulmonary alveolar proteinosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 200 2019, Nr. 7, S. 881 – 887
-
The Burden of Sarcoidosis Symptoms from a Patient PerspectiveIn: Lung , Jg. 197 2019, Nr. 2, S. 155 – 161DOI (Open Access)
-
Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial PneumoniaIn: Respiration: International Journal of Thoracic Medicine , Jg. 98 2019, Nr. 1, S. 29 – 37DOI, Online Volltext (Open Access)
-
An emerging frontier in the treatment of acute exacerbation of idiopathic pulmonary fibrosisIn: Respiratory Investigation , Jg. 56 2018, Nr. 2, S. 97 – 99
-
Anti-Interleukin-5-Therapie und eosinophile Granulomatose mit Polyangiitis : Ein Aufbruch?In: Der Pneumologe , Jg. 15 2018, Nr. 3, S. 189 – 192
-
Anti-acid therapy in idiopathic pulmonary fibrosis : insights from the INPULSIS® trialsIn: Respiratory Research , Jg. 19 2018, S. 167DOI (Open Access)
-
Differenzialdiagnose interstitieller LungenerkrankungenIn: Der Pneumologe , Jg. 15 2018, Nr. 6, S. 413 – 418
-
Effect of pirfenidone on exercise capacity and dyspnea in patients with idiopathic pulmonary fibrosis (IPF) and more advanced lung function impairmentIn: Chest , Jg. 154 2018, Nr. Suppl. 4, S. 432A – 433A
-
Eosinophile Granulomatose und Polyangiitis : Diagnostik und TherapieIn: Der Pneumologe , Jg. 15 2018, Nr. 5, S. 333 – 343
-
Eosinophile Granulozyten : physiologische und pathophysiologische FunktionenIn: Der Pneumologe , Jg. 15 2018, Nr. 5, S. 299 – 308
-
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis : Uncertainties and ControversiesIn: Respiration: International Journal of Thoracic Medicine , Jg. 96 2018, Nr. 6, S. 571 – 587
-
German Guideline for Idiopathic Pulmonary Fibrosis : Update on Pharmacological Therapies 2017In: Pneumologie , Jg. 72 2018, Nr. 2, S. 155 – 168DOI (Open Access)
-
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib : results from the TOMORROW trial and its open-label extensionIn: Thorax , Jg. 73 2018, Nr. 6, S. 581 – 583DOI (Open Access)
-
Modified GAP stage as a predictor of acute exacerbation in idiopathic pulmonary fibrosisIn: European Respiratory Journal (ERJ) , Jg. 52 2018, Nr. Suppl. 62, S. PA2907
-
Nailfold capillaroscopy findings in ILD patients : results from a single centre investigationIn: European Respiratory Journal (ERJ) , Jg. 52 2018, Nr. Suppl. 62, S. PA2951
-
Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen - klinische Sektion der DGPIn: Pneumologie , Jg. 72 2018, Nr. 6, S. 446 – 457
-
Patterns of discontinuation in patients with IPF treated with open-label nintedanib : data from INPULSIS-ONIn: European Respiratory Journal (ERJ) , Jg. 52 2018, Nr. Suppl. 62, S. PA4777DOI (Open Access)
-
Phenotypes of organ involvement in sarcoidosisIn: European Respiratory Journal (ERJ) , Jg. 51 2018, Nr. 1, S. 1700991DOI (Open Access)
-
Serum YKL-40 in workers at an indium-tin oxide production facility - ReplyIn: Respirology , Jg. 23 2018, Nr. 3, S. 342DOI (Open Access)
-
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisIn: Respiration: International Journal of Thoracic Medicine , Jg. 95 2018, Nr. 5, S. 317 – 326DOI (Open Access)
-
The European IPF Registry : Addressing challenges and characteristics of patients with Idiopathic Pulmonary FibrosisIn: European Respiratory Journal (ERJ) , Jg. 52 2018, Nr. Suppl. 62, S. PA2198
-
The European IPF registry (eurIPFreg) : baseline characteristics and survival of patients with idiopathic pulmonary fibrosisIn: Respiratory Research , Jg. 19 2018, S. 141DOI (Open Access)
-
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)In: Respiration: International Journal of Thoracic Medicine , Jg. 94 2017, Nr. 5, S. 408 – 415DOI (Open Access)
-
Annual rate of FVC decline in Patients with IPF treared with Pirfenidone : Pooled Analysis (Encore)In: Respirology , Jg. 22 2017, Nr. Suppl. 2, S. 79DOI (Open Access)
-
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received PirfenidoneIn: Respiration: International Journal of Thoracic Medicine , Jg. 93 2017, Nr. 6, S. 415 – 423DOI (Open Access)
-
Differential diagnosis of granulomatous lung disease : Clues and pitfallsIn: European Respiratory Review (ERR) , Jg. 26 2017, Nr. 145, 170012DOI (Open Access)
-
Effect of continued Pirfenidone treatment following >= 15% decline in 6MWD in IPF Patients-Pooled Analysis (Encore)In: Respirology , Jg. 22 2017, Nr. Suppl. 2, S. 79DOI (Open Access)
-
Effect of pirfenidone on mortality : pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosisIn: The Lancet Respiratory Medicine , Jg. 5 2017, Nr. 1, S. 33 – 41
-
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosisIn: Thorax , Jg. 72 2017, Nr. 2, S. 148 – 153DOI (Open Access)
-
Eosinophile Granulomatose und Polyangiitis (Churg-Strauss-Syndrom) : Pathogenetische und klinische Grundlagen, Diagnostik und BehandlungszugāngeIn: Arzneimitteltherapie (AMT) , Jg. 35 2017, Nr. 11, S. 413 – 426
-
Epidemiologie und klinisches Erscheinungsbild der SarkoidoseIn: Klinische Monatsblätter für Augenheilkunde , Jg. 234 2017, Nr. 6, S. 790 – 795
-
Erfahrungen und unterstützende Hinweise zur Anwendung von Nintedanib bei Patienten mit idiopathischer LungenfibroseIn: Pneumologie , Jg. 71 2017, Nr. 9, S. 567 – 579
-
FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosisIn: Respiratory Medicine , Jg. 123 2017, S. 105 – 109
-
Helicobacter Pylori As A Risk Factor For Acute Exacerbation In Idiopathic Pulmonary FibrosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 195 2017, S. A3468
-
Idiopathic pleuroparenchymal fibroelastosis (PPFE) : A case study of a rare entityIn: Revista Portuguesa de Pneumologia (English Edition) , Jg. 23 2017, Nr. 6, S. 352 – 355DOI (Open Access)
-
M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco : analysis of pooled data from ascend and capacityIn: Thorax , Jg. 72 2017, Nr. Suppl. 3, A254
-
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisIn: European Respiratory Review (ERR) , Jg. 26 2017, Nr. 146, 170057DOI (Open Access)
-
Potential Utility Of Anti Dfs70 Antibodies To Exclude Systemic Autoimmune Rheumatic Disease (sard) In Patients With Interstitial Lung Disease (ild)In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 195 2017, S. A7129
-
Quartile Forced Vital Capacity Changes At 3, 6, 9, And 12 Months With Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis : A Pooled Phase Iii AnalysisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 195 2017, S. A5395
-
Reply : Effect of Nintedanib in Patients with Idiopathic Pulmonary FibrosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 195 2017, Nr. 9, S. 1275
-
Reply [Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis ]In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 195 2017, Nr. 9, S. 1275
-
S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017In: Pneumologie , Jg. 71 2017, Nr. 7, S. 460 – U140
-
Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitisIn: European Respiratory Journal (ERJ) , Jg. 49 2017, Nr. 2
-
Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosisIn: Respirology , Jg. 22 2017, Nr. 7, S. 1371 – 1378
-
Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease : Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments-Diagnostic Yield and ComplicationsIn: Respiration: International Journal of Thoracic Medicine , Jg. 93 2017, Nr. 4, S. 285 – 292DOI (Open Access)
-
A Global Survey on Whole Lung Lavage in Pulmonary Alveolar ProteinosisIn: Chest , Jg. 150 2016, Nr. 1, S. 251 – 253
-
A confusing case report of pulmonary langerhans cell histiocytosis and literature reviewIn: Open Medicine , Jg. 11 2016, Nr. 1, S. 178 – 182DOI (Open Access)
-
An Important Step Forward, but Still a Way to GoIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 193 2016, Nr. 3, S. 340 – 341
-
Analysis of Patients With Idiopathic Pulmonary Fibrosis (IPF) With More Severe Lung Function Impairment Treated With Pirfenidone in RecapIn: Chest , Jg. 150 2016, Nr. 4 Suppl., S. 537A
-
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis : a pooled analysisIn: The Lancet Respiratory Medicine , Jg. 4 2016, Nr. 5, S. 381 – 389DOI (Open Access)
-
Anti-acid treatment in patients with IPF : interpret results from post-hoc, subgroup, and exploratory analyses with great caution – Authors' replyIn: The Lancet Respiratory Medicine , Jg. 4 2016, Nr. 9, S. e48
-
Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary FibrosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 193 2016, Nr. 7, S. 745 – 752
-
Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies : A Retrospective Analysis of a Large Austrian RegistryIn: Respiration: International Journal of Thoracic Medicine , Jg. 91 2016, Nr. 1, S. 26 – 33
-
Clinical Spectrum Time Course in Non Anti Jo-1 Positive Antisynthetase SyndromeIn: Annals of the Rheumatic Diseases (ARD) , Jg. 75 2016, Nr. Suppl. 2, S. 540 – 541
-
Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle LungenerkrankungenIn: Pneumologie , Jg. 70 2016, Nr. 11, S. 742 – 746
-
Effect Of Continued Treatment With Pirfenidone Following A >= 10% Relative Decline In Percent Predicted Forced Vital Capacity In Patients With Idiopathic Pulmonary Fibrosis (ipf)In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 193 2016, S. A4995
-
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity : analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisIn: Thorax , Jg. 71 2016, Nr. 5, S. 429 – 435
-
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung functionIn: European Respiratory Journal (ERJ) , Jg. 48 2016, Nr. 3, S. 843 – 851
-
Erratum: 58-year old woman with primary biliary cirrhosis and crepitationsIn: Deutsche Medizinische Wochenschrift - DMW , Jg. 141 2016, Nr. 4, S. 241
-
Fam13a Polymorphism As A Prognostic Factor In Patients With Idiopathic Pulmonary FibrosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 193 2016, S. A4982
-
How to handle IPF – the new Portuguese consensus documentIn: Revista Portuguesa de Pneumologia (English Edition) , Jg. 22 2016, Nr. 2, S. 70 – 72DOI (Open Access)
-
Interstitial pneumonia with autoimmune features : a critical appraisal of the new definitionIn: Current Opinion in Pulmonary Medicine , Jg. 22 2016, Nr. 5, S. 442 – 449
-
Long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis : pooled analysis of 4 clinical trialsIn: Thorax , Jg. 71 2016, Nr. Suppl. 3, S. A175 – A176
-
MFAP4 : A candidate biomarker for hepatic and pulmonary fibrosis?In: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 33 2016, Nr. 1, S. 41 – 50
-
MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosisIn: Orphanet Journal of Rare Diseases , Jg. 11 2016, S. 48DOI (Open Access)
-
Pirfenidone for idiopathic pulmonary fibrosis : analysis of pooled data from three multinational phase 3 trialsIn: European Respiratory Journal (ERJ) , Jg. 47 2016, Nr. 1, S. 243 – 253DOI (Open Access)
-
Pulmonary alveolar proteinosis : Another autoimmune disease associated with sarcoidosis?In: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 33 2016, Nr. 1, S. 90 – 94
-
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis : integrated analysis of cumulative data from 5 clinical trialsIn: BMJ Open Respiratory Research , Jg. 3 2016, S. e000105DOI (Open Access)
-
Sarcoidosis in America. Analysis Based on Health Care UseIn: Annals of the American Thoracic Society , Jg. 13 2016, Nr. 8, S. 1244 – 1252
-
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosisIn: European Respiratory Journal (ERJ) , Jg. 47 2016, Nr. 6, S. 1776 – 1784DOI (Open Access)
-
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis : methodological concernsIn: European Respiratory Journal (ERJ) , Jg. 48 2016, Nr. 5, S. 1524 – 1526DOI (Open Access)
-
Annual rate of fvc decline in various patient sub-groups with idiopathic pulmonary fibrosis treated with pirfenidone : pooled analysis from 3 pivotal studiesIn: Thorax , Jg. 71 2016, Nr. Suppl. 3, S. A57
-
Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis (IPF) under pirfenidone treatmentIn: Thorax , Jg. 71 2016, Nr. Suppl. 3, S. A58
-
Cumulative distribution of patients by change in FVC% predicted in the inpulsis® trials of NINTEDANIB in patients with idiopathic pulmonary fibrosisIn: Thorax , Jg. 71 2016, Nr. Suppl. 3, S. A59 – A59
-
(100) - KL-6 Changes in Serum Can Be Predictive of Chronic Lung Allograft Dysfunction in Lung Transplant RecipientsIn: The Journal of Heart and Lung Transplantation , Jg. 34 2015, Nr. 4 Suppl., S. 46
-
58-jährige Patientin mit primär biliärer Zirrhose und KnisterrasselnIn: Deutsche Medizinische Wochenschrift - DMW , Jg. 140 2015, Nr. 24, S. 1847
-
Antiacid therapy and progression free survival in idiopathic pulmonary fibrosis (IPF)In: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. OA3478
-
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis : a phase 2 trial of carlumabIn: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. 6, S. 1740 – 1750DOI (Open Access)
-
Challenges in IPF diagnosis, current management and future perspectivesIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 32 2015, Nr. 1S, S. 28 – 35
-
Comparative analysis of multiple gene polymorphisms for acute exacerbation of idiopathic pulmonary fibrosisIn: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. OA3510
-
Determination of a single nucleotide polymorphism (SNP) of the TNFalpha-R1 region (TNFRSF1A) in patients with lung sarcoidosis : Preliminary resultsIn: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. PA3321
-
Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)In: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. OA3479
-
Diagnosis of sarcoidosisIn: Clinical Reviews in Allergy and Immunology , Jg. 49 2015, Nr. 1, S. 54 – 62
-
Different biopsy techniques for confirmation of sarcoidosis: The game for the best diagnostic yield is still openIn: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. PA3326
-
Effect of Pirfenidone on All-Cause Mortality in Patients With Idiopathic Pulmonary Fibrosis (IPF) : Comparison of Pooled Analysis With Meta-analysis From the ASCEND and CAPACITY TrialsIn: Chest , Jg. 148 2015, Nr. 4, S. 363A – 363B
-
Effect of Pirfenidone on IPF-Related Mortality Outcome Measures in Patients With Idiopathic Pulmonary Fibrosis (IPF) : Pooled Data Analysis From the ASCEND and CAPACITY TrialsIn: Chest , Jg. 148 2015, Nr. 4, S. 391A – 391B
-
Effect of anti-acid medication on reduction in FVC decline with nintedanibIn: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. OA4502
-
Effect of anti-acid medication on reduction in FVC decline with nintedanibIn: Respirology , Jg. 20 2015, Nr. S3, S. 84 – 84
-
Effect of baseline FVC on lung function decline with nintedanib : Results from the inpulsis trialsIn: Respirology , Jg. 20 2015, Nr. S 2, S. 87 – 87
-
Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF)In: Thorax , Jg. 70 2015, S. A62 – A63
-
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)In: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. PA3054
-
Efficacy and safety of nintedanib in patients with IPF beyond week 52 : Data from the Phase II TOMORROW trialIn: Thorax , Jg. 70 2015, S. A63 – A64
-
Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosisIn: Immunobiology , Jg. 220 2015, Nr. 3, S. 382 – 388
-
GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disordersIn: BMC Pulmonary Medicine , Jg. 15 2015, S. 87DOI (Open Access)
-
Hypersensitivity Pneumonitis : A Comprehensive ReviewIn: Journal of Investigational Allergology and Clinical Immunology , Jg. 25 2015, Nr. 4, S. 237 – 250
-
Infliximab for chronic cutaneous sarcoidosis : a subset analysis from a double-blind randomized clinical trialIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 32 2015, Nr. 4, S. 289 – 295
-
MUC 5 B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosisIn: Respirology , Jg. 20 2015, Nr. 3, S. 439 – 444
-
Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) with more preserved lung functionIn: Thorax , Jg. 70 2015, Nr. Suppl 3, S. A81 – A81
-
Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)In: Pneumologie , Jg. 69 2015, Nr. 8, S. 455 – 458
-
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) : Integrated analysis of cumulative data from 5 clinical trialsIn: Thorax , Jg. 70 2015, S. A80 – A81
-
Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD)In: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. PA3803
-
Sporadic idiopathic non-specific interstitial pneumonia in monozygotic twin sistersIn: European Respiratory Journal (ERJ) , Jg. 46 2015, Nr. Suppl. 59, S. PA3827
-
The changing treatment landscape in idiopathic pulmonary fibrosisIn: European Respiratory Review (ERR) , Jg. 24 2015, Nr. 135, S. 65 – 68
-
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisIn: Respiratory Medicine , Jg. 109 2015, Nr. 7, S. 914 – 922DOI (Open Access)
-
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosisIn: European Respiratory Journal (ERJ) , Jg. 43 2014, Nr. 5, S. 1421 – 1429
-
A pilot study : a combined therapy using polymyxin-B hemoperfusion and extracorporeal membrane oxygenation for acute exacerbation of interstitial pneumoniaIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 31 2014, Nr. 4, S. 343 – 349
-
All-cause mortality rate in patients with idiopathic pulmonary fibrosis : Implications for the design and execution of clinical trialsIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 189 2014, Nr. 7, S. 825 – 831DOI (Open Access)
-
Alveolar and intraparenchymal proteasome in sarcoidosisIn: Respiratory Medicine , Jg. 108 2014, Nr. 10, S. 1534 – 1541
-
Analysis of lung function and survival in RECAP : An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosisIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 31 2014, Nr. 3, S. 198 – 205
-
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosisIn: Respiratory Medicine , Jg. 108 2014, Nr. 7, S. 1031 – 1039
-
Biomarkers in connective tissue disease-associated interstitial lung diseaseIn: Seminars in Respiratory and Critical Care Medicine , Jg. 35 2014, Nr. 2, S. 181 – 200
-
Combination therapy : The future of management for idiopathic pulmonary fibrosis?In: The Lancet Respiratory Medicine , Jg. 2 2014, Nr. 11, S. 933 – 942
-
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosisIn: Respirology , Jg. 19 2014, Nr. 5, S. 740 – 747DOI (Open Access)
-
Diagnostik und Therapie der kardialen SarkoidoseIn: Pneumologie , Jg. 68 2014, Nr. 2, S. 124 – 132
-
Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphismsIn: BMC Medical Genetics , Jg. 15 2014, S. 4DOI (Open Access)
-
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisIn: The New England Journal of Medicine , Jg. 370 2014, Nr. 22, S. 2071 – 2082
-
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis : Results of two 52-week, phase III, randomized, placebo-controlled trials (INPULSIS (TM))In: Respirology , Jg. 19 2014, Nr. Suppl. 3, S. 28
-
Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse EventsIn: Advances in Therapy , Jg. 31 2014, Nr. 5, S. 575 – 576
-
Interstitial lung diseaseIn: European Respiratory Review (ERR) , Jg. 23 2014, Nr. 131, S. 40 – 54DOI (Open Access)
-
Konsensuspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) und der Deutschen Gesellschaft für Kardiologie – Herz und Kreislaufforschung (DGK) zur Diagnostik und Therapie der kardialen SarkoidoseIn: Der Kardiologe , Jg. 8 2014, Nr. 1, S. 13 – 85
-
Pirfenidone in Idiopathic Pulmonary Fibrosis : Expert Panel Discussion on the Management of Drug-Related Adverse EventsIn: Advances in Therapy , Jg. 31 2014, Nr. 4, S. 375 – 391DOI (Open Access)
-
S12 Effect Of Baseline Fvc On Decline In Lung Function With Nintedanib : Results From The Inpulsis TrialsIn: Thorax , Jg. 69 2014, Nr. Suppl. 2, S. A9
-
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosisIn: European Respiratory Journal (ERJ) , Jg. 44 2014, Nr. 5, S. 1296 – 1307
-
Serum KL-6 Levels Are Associated With Long-Term Prognosis in Lung Transplant RecipientsIn: The Journal of Heart and Lung Transplantation , Jg. 33 2014, Nr. 4 Suppl., S. S190 – S191
-
Smoking-related idiopathic interstitial pneumoniaIn: European Respiratory Journal (ERJ) , Jg. 44 2014, Nr. 3, S. 594 – 602
-
The WASOG sarcoidosis organ assessment instrument : An update of a previous clinical toolIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 31 2014, Nr. 1, S. 19 – 27
-
The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids : A retrospective analysis from a randomized clinical trialIn: Respiratory Medicine , Jg. 108 2014, Nr. 1, S. 189 – 194
-
55-jährige Patientin mit progredienter Belastungsdyspnoe und radiologischen LungenveränderungenIn: Deutsche Medizinische Wochenschrift - DMW , Jg. 138 2013, Nr. 11, S. 535 – 536
-
An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumoniasIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 188 2013, Nr. 6, S. 733 – 748
-
CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseasesIn: Respiratory Medicine , Jg. 107 2013, Nr. 9, S. 1444 – 1452
-
Die deutsche IPF-Leitlinie : national vs. internationalIn: Pneumologie , Jg. 67 2013, Nr. 2, S. 79 – 80
-
EBUS-TBNA for the Diagnosis of Sarcoidosis : Is it the Only Game in Town?In: Journal of Bronchology & Interventional Pulmonology , Jg. 20 2013, Nr. 3, S. 195 – 197
-
Ethnic difference and serum KL-6 as predictors for acute exacerbation of idiopathic pulmonary fibrosisIn: Respirology , Jg. 18 2013, Nr. Suppl. 4, S. 58
-
Idiopathic pulmonary fibrosis in 2011 : key updates on guidelines and therapeuticsIn: Respiratory Research , Jg. 14 2013, Nr. Suppl. 1
-
Idiopathic pulmonary fibrosis in 2011 : Key updates on guidelines and therapeutics. Concluding remarksIn: Respiratory Research , Jg. 14 2013, Nr. Suppl. 1, S. 8
-
Interstitielle Lungenerkrankungen : Fortschritte in den letzten 10 Jahren und Perspektiven für die weitere EntwicklungIn: Der Pneumologe , Jg. 10 2013, Nr. Suppl. 1, S. 47 – 52
-
Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen LungenfibroseIn: Deutsche Medizinische Wochenschrift - DMW , Jg. 138 2013, Nr. 11, S. 518 – 523
-
Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumoniaIn: Immunobiology , Jg. 218 2013, Nr. 6, S. 930 – 937
-
Om Prakash Sharma, MD, FRCP, FCCP - 4 July 1936 - 19 August 2012 : Internationally acclaimed specialist in sarcoidosisIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 30 2013, Nr. 3, S. 166
-
S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen LungenfibroseIn: Pneumologie , Jg. 67 2013, Nr. 2, S. 81 – 111
-
Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosisIn: Orphanet Journal of Rare Diseases , Jg. 8 2013, Nr. 1, S. 53DOI (Open Access)
-
Treatment of idiopathic pulmonary fibrosis with ambrisentan : a parallel, randomized trialIn: Annals of Internal Medicine , Jg. 158 2013, Nr. 9, S. 641 – 649
-
An Official American Thoracic Society Clinical Practice Guideline : The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung DiseaseIn: Critical Care Medicine , Jg. 185 2012, Nr. 9, S. 1004 – 1014
-
Assays for laboratory confirmation of novel human coronavirus (HCOV-EMC) infectionsIn: Eurosurveillance , Jg. 17 2012, Nr. 49, S. 2 – 10DOI (Open Access)
-
Chronic Hypersensitivity PneumonitisIn: Clinics in Chest Medicine , Jg. 33 2012, Nr. 1, S. 151 – 163
-
Diagnostic approach to interstitial pneumonias in a single centre : report on 88 casesIn: Diagnostic Pathology , Jg. 7 2012, S. 160DOI, Online Volltext (Open Access)
-
Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levelsIn: Respiratory Medicine , Jg. 106 2012, Nr. 12, S. 1756 – 1764
-
Distinct proteasome subpopulations in the alveolar space of patients with the acute respiratory distress syndromeIn: Mediators of Inflammation 2012, 204250DOI (Open Access)
-
Hypersensitivity PneumonitisIn: Immunology and Allergy Clinics of North America , Jg. 32 2012, Nr. 4, S. 537 – 556
-
KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndromeIn: Orphanet Journal of Rare Diseases , Jg. 7 2012, Nr. 1, S. 99DOI (Open Access)
-
Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacteriumIn: Modern Pathology , Jg. 25 2012, Nr. 9, S. 1284 – 1297DOI (Open Access)
-
Prof. Om Prakash Sharma, 1936-2012In: European Respiratory Journal (ERJ) , Jg. 40 2012, Nr. 5, S. 1078 – 1080
-
The European Respiratory Society spirometry tent : a unique form of screening for airway obstructionIn: European Respiratory Journal (ERJ) , Jg. 39 2012, Nr. 6, S. 1458 – 1467DOI (Open Access)
-
Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosisIn: European Respiratory Journal (ERJ) , Jg. 40 2012, Nr. 6, S. 1468 – 1474
-
An Official ATS/ERS/JRS/ALAT Statement : Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 183 2011, Nr. 6, S. 788 – 824
-
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 184 2011, Nr. 4, S. 459 – 466
-
Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantationIn: The Journal of Heart and Lung Transplantation , Jg. 30 2011, Nr. 12, S. 1374 – 1380
-
Defining the clinical outcome status (COS) in sarcoidosis : Results of WASOG Task ForceIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 28 2011, Nr. 1, S. 56 – 64
-
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosisIn: The New England Journal of Medicine , Jg. 365 2011, Nr. 12, S. 1079 – 1087
-
Emerging potential treatments : New hope for idiopathic pulmonary fibrosis patients?In: European Respiratory Review (ERR) , Jg. 20 2011, Nr. 121, S. 201 – 207
-
Forced vital capacity in patients with idiopathic pulmonary fibrosis : test properties and minimal clinically important differenceIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 184 2011, Nr. 12, S. 1382 – 1389
-
Increased expression of tumor necrosis factor receptors in cryptogenic organizing pneumoniaIn: Respiratory Medicine , Jg. 105 2011, Nr. 2, S. 292 – 297DOI (Open Access)
-
Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosisIn: Clinical and Vaccine Immunology , Jg. 18 2011, Nr. 6, S. 931 – 939DOI (Open Access)
-
Lungensarkoidose : Diagnostik und TherapieIn: Tägliche Praxis , Jg. 52 2011, Nr. 3, S. 463 – 472
-
Lungensarkoidose : Diagnostik und TherapieIn: Gynäkologische Praxis , Jg. 35 2011, Nr. 3, S. 473 – 482
-
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY) : two randomised trialsIn: Lancet , Jg. 377 2011, S. 1760 – 1769
-
Pulmonary alveolar proteinosis : New insights from a single-center cohort of 70 patientsIn: Respiratory Medicine , Jg. 105 2011, Nr. 12, S. 1908 – 1916
-
Six-minute-walk test in idiopathic pulmonary fibrosis : Test validation and minimal clinically important differenceIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 183 2011, Nr. 9, S. 1231 – 1237
-
Stellungnahme der DGP zur Pressemitteilung des National Heart, Lung, and Blood Institute zur PANTHER-Studie bei IPF-Patienten vom 21.10. 2011In: Pneumologie , Jg. 65 2011, Nr. 12, S. 724 – 725
-
Surfactant protein D and KL-6 serum levels in systemic sclerosis: Correlation with lung and systemic involvementIn: Sarcoidosis Vasculitis and Diffuse Lung Diseases , Jg. 28 2011, Nr. 1, S. 27 – 33
-
Treatment of pulmonary fibrosis : New substances and new interventionsIn: Der Internist , Jg. 52 2011, Nr. 12, S. 1422 – 1428
-
A female soccer player with recurrent haemoptysis and iron deficiency anaemia : idiopathic pulmonary haemosiderosis (IPH)-case report and literature reviewIn: BMJ Case Reports 2010
-
Angiogenic and angiostatic chemokines in idiopathic pulmonary fibrosis and granulomatous lung diseaseIn: Respiration: International Journal of Thoracic Medicine , Jg. 80 2010, Nr. 5, S. 372 – 378DOI (Open Access)
-
Diagnostic modalities in sarcoidosis: BAL, EBUS, and PETIn: Seminars in Respiratory and Critical Care Medicine , Jg. 31 2010, Nr. 4, S. 404 – 408
-
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosisIn: European Respiratory Journal (ERJ) , Jg. 35 2010, Nr. 1, S. 14 – 26DOI (Open Access)
-
Interstitielle Lungenerkrankungen – historische Entwicklung, Status quo und AusblickIn: Pneumologie , Jg. 64 2010, Nr. 9, S. 573 – 576
-
SarcoidosisIn: Seminars in Respiratory and Critical Care Medicine , Jg. 31 2010, Nr. 4, S. 373 – 374
-
The International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platformIn: Lymphatic Research and Biology , Jg. 8 2010, Nr. 1, S. 81 – 87
-
Alveolar extracellular 20s proteasome in patients with acute respiratory distress syndromeIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 179 2009, Nr. 12, S. 1098 – 1106
-
CD4⁺CD25⁺ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosisIn: Nephrology Dialysis Transplantation (NDT) , Jg. 24 2009, Nr. 1, S. 161 – 171DOI (Open Access)
-
Esophageal sarcoidosis presenting as pseudodiverticulumIn: Sarcoidosis, Vasculitis and Diffuse Lung Diseases , Jg. 25 2008, Nr. 1, S. 64 – 67
-
Interstitielle LungenerkrankungenIn: Zeitschrift für Pneumologie , Jg. 20 2023, Nr. 6, S. 297 – 299DOI (Open Access)
-
Der Pneumologe wird zur Zeitschrift für Pneumologie : Zur Titeländerung Ihrer ZeitschriftIn: Zeitschrift für Pneumologie , Jg. 19 2022, Nr. 4, S. 187 – 188DOI (Open Access)
-
The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis : Is it of diagnostic value?In: European Respiratory Journal (ERJ) , Jg. 56 2020, Nr. 2, S. 2001534DOI (Open Access)
-
When the Game Changes : Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 PandemicIn: Chest , Jg. 158 2020, Nr. 3, S. 892 – 895DOI (Open Access)
-
Guest editorsIn: Idiopathic pulmonary fibrosis / Costabel, Ulrich; Crestani, Bruno; Wells, Athol U. (Hrsg.) 2016, S. VII – IX
-
IntroductionIn: Idiopathic pulmonary fibrosis / Costabel, Ulrich; Crestani, Bruno; Wells, Athol U. (Hrsg.) 2016, S. X – XI
-
Pneumologie im Wandel : eine StandortbestimmungIn: Deutsche Medizinische Wochenschrift - DMW , Jg. 138 2013, Nr. 11, S. 517
-
Hot of the breath : Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the goodIn: Thorax , Jg. 67 2012, Nr. 11, S. 938 – 940
-
Idiopathic pulmonary fibrosis : recent milestones in disease managementIn: European Respiratory Review (ERR) , Jg. 21 2012, Nr. 124, S. 140DOI (Open Access)
-
Triple therapy in idiopathic pulmonary fibrosis : an alarming press releaseIn: European Respiratory Journal (ERJ) , Jg. 39 2012, Nr. 4, S. 805 – 806
-
Pulmonary alveolar proteinosis associated with dust inhalation : Not secondary but autoimmune?In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 181 2010, Nr. 5, S. 427 – 428
-
Clinical Relevance of Lipid-laden Macrophages in the Bronchoalveolar Lavage (BAL) Fluid of Patients With Interstitial Lung Disease (ILD)In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 211 2025, Nr. Suppl., S. A3525 – A3525
-
Prognostic relevance of autoantibodies in patients with hypersensitivity pneumonitis (HP) : A German multicentre study
European-Respiratory-Society Congress (ERS); SEP 07-11, 2024; Vienna, Austria,In: European Respiratory Journal (ERJ) , Jg. 64 2024, Nr. Suppl. 68, PA2453 -
Die Etablierung einer durchflusszytometrischen Multiparameter-Analyse der BAL und ihre Validierung durch Korrelation mit den Befunden der lichtmikroskopischen Routinediagnostik
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie , Jg. 77 2023, Nr. S 01, S. S85 – S86 -
Progrediente Pulmonale Fibrose (PPF) bei Patienten mit exogen allergischer Alveolitis
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie , Jg. 77 2023, Nr. S 01, S. S102 -
COVID-19 in patients with Pulmonary Alveolar Proteinosis : A European multicenter study
ERS International Congress 2022 ; 4-6 September 2022, Barcelona, Spain and online,In: European Respiratory Journal (ERJ) , Jg. 60 2022, Nr. Supplement 66 -
Comparison of a new Punch Needle with a conventional 22-gauge Needle in EBUS-TBNA in Patients with suspected Sarcoidosis
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie , Jg. 76 2022, Nr. Supplement 1, S. S44 -
Comparison of a 22G crown-cut needle with a conventional 22G needle with EBUS guidance in diagnosis of sarcoidosisIn: European Respiratory Journal (ERJ) , Jg. 58 2021, Nr. Suppl. 65, PA2454DOI (Open Access)
-
Histological confidence of transbronchial cryobiopsy in interstitial lung diseases is influenced by sample sizeIn: European Respiratory Journal (ERJ) , Jg. 58 2021, Nr. Suppl. 65, OA233DOI (Open Access)
-
Prevalence and quantification of thoracic pain (TP) through quantitative sensory testing (QST) in patients with chronic interstitial lung disease (cILD)In: European Respiratory Journal (ERJ) , Jg. 58 2021, Nr. Suppl. 65, PA2343
-
Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA)In: European Respiratory Journal (ERJ) , Jg. 58 2021, Nr. Suppl. 65, RCT2904DOI (Open Access)
-
Association between weight loss and decline in FVC in patients with IPF
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28.03.2020 (verschoben auf 2021); Leipzig,In: Pneumologie , Jg. 74 2020, Nr. Suppl. 1, S. S100 – S101 -
Cytokines, chemokines and growth factors concentration in BAL fluid from patients with Idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP)
ERS Virtual Congress 2020,In: European Respiratory Journal (ERJ) , Jg. 56 2020, Nr. Suppl. 64DOI (Open Access) -
Cytokines, chemokines and growth factors concentration in BAL fluid from patients with idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP)
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28.03.2020 (verschoben auf 2021); Leipzig,In: Pneumologie , Jg. 74 2020, Nr. Suppl. 1, S. S90 – S91 -
Disease Progression Events in Trials of Nintedanib in Patients with Idiopathic Pulmonary FibrosisIn: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 201 2020, S. A4548
-
Klinische Nutzbarkeit eines mit Serum KL-6 modifizierten GAP-Indexes bei Patienten mit interstitiellen Lungenerkrankungen (ILD)
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28.03.2020 (verschoben auf 2021); Leipzig,In: Pneumologie , Jg. 74 2020, Nr. Suppl. 1, S. S10 -
Nintedanib dose adjustments and adverse events in patients with progressive autoimmune disease-related interstitial lung diseases in the inbuild trialIn: Annals of the Rheumatic Diseases (ARD) , Jg. 79 2020, Nr. Suppl. 1, S. 1015DOI (Open Access)
-
Potential Clinical Utility of Serum KL-6 for Improving the GAP-Staging in Patients with Interstitial Lung Diseases (ILD)
ATS 2020 International Conference, 15.-20. Mai 2020, Philadelphia, USA - abgesagt,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 201 2020, S. A4037 -
Safety and Tolerability of Nintedanib in Patients with Fibrosing ILDs : a Comparison of the INBUILD and INPULSIS Trials
ATS 2020 International Conference, 15.-20. Mai 2020, Philadelphia, USA - abgesagt,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 201 2020, S. A1506 -
The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD)
ERS International Congress 2020,In: European Respiratory Journal (ERJ) , Jg. 56 2020, Nr. Suppl. 64DOI (Open Access) -
A comparison of existing questionnaires for identifying the causes of interstitial and rare lung diseasesIn: European Respiratory Journal (ERJ) , Jg. 54 2019, Nr. Suppl. 63, S. PA4728DOI (Open Access)
-
Potential Clinical Utility of MUC5B and TOLLIP Single Nucleotide Polymorphisms (SNP) in the Management of Patients with IPF : Preliminary Results
Herbsttagung der Sektion Zellbiologie in der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., Essen, 09.–10.11.2018,In: Pneumologie , Jg. 73 2019, Nr. 02, S. 113 -
Potential clinical utility of MUC5B and TOLLIP single nucleotide polymorphisms (SNP) in in the management of patients with IPFIn: European Respiratory Journal (ERJ) , Jg. 54 2019, Nr. Suppl. 63, S. PA5370DOI (Open Access)
-
Safety and pharmacokinetics of nintedanib plus sildenafil in the INSTAGE trialIn: European Respiratory Journal (ERJ) , Jg. 54 2019, Nr. Suppl. 63, S. PA1354DOI (Open Access)
-
Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassayIn: European Respiratory Journal (ERJ) , Jg. 54 2019, Nr. Suppl. 63, S. PA4697DOI (Open Access)
-
Clinical Relevance of Antinuclear Antibodies (ANA) in Patients with Hypersensitivity Pneumonitis (HP) : A Single Centre Experience
International Conference of the American Thoracic Society 2018 ; ATS 2018 ; May 18-23, 2018. San Diego,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 197 2018, Nr. 9, abstract issue, S. A3019 -
Multiple progression events in patients with idiopathic pulmonary fibrosis (IPF)
Annual Scientific Meeting of the Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) ; 23–27 March 2018, Adelaide,In: Respirology , Jg. 23 2018, Nr. Suppl. 1, S. 102DOI (Open Access) -
The RIFF Study (Cohort B) : A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Lebrikizumab in Combination with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
International Conference of the American Thoracic Society 2018 ; ATS 2018 ; May 18-23, 2018, San Diego,In: American Journal of Respiratory and Critical Care Medicine (AJRCCM) , Jg. 197 2018, Nr. 9, abstract issue, S. A6168 -
BAL findings in interstitial lung diseaseIn: Bronchoalveolar Lavage in Basic Research and Clinical Medicine / Schildgen, Oliver; Schildgen, Verena; Brockmann, Michael (Hrsg.) 2023, S. 66 – 93
-
Definition and history of sarcoidosisIn: Sarcoidosis / Bonella, Francesco; Culver, Daniel A.; Israël-Biet, Dominique (Hrsg.) 2022, S. 1 – 7
-
Idiopathic pulmonary fibrosisLausanne: European Respiratory Society 2016
(ERS Monograph ; 71) -
Progressive pulmonary fibrosis in patients with chronic hypersensitivity pneumonitis (cHP) : a single center experience
International Congress of the European Respiratory Society (ERS) 2023 ; 9 - 13 September 2023, Milan, Italy,In: European Respiratory Journal (ERJ) , Jg. 62 2023, Nr. Supplement 67: ERS International Congress 2023 abstracts, PA2883